Method for treating a TRPV1-mediated disease
View Patent ↗A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: wherein A represents a lower alkylene group or a lower alkenylene group; R 1 represents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and R 2 and R 3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.
1. A method for treating a TRPV1-mediated disease, comprising administering to a patient a therapeutically effective amount of a compound, or a salt thereof, represented by the following formula [I]:
wherein A represents a lower alkylene group or a lower alkenylene group; R 1 represents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and R 2 and R 3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group, wherein the TRPV1-mediated disease is selected from the group consisting of pain, an overactive bladder and a gastrointestinal dysfunction.
2. The method according to claim 1 , wherein
A is a lower alkylene group or a lower alkenylene group;
R 1 is an unsubstituted or substituted lower alkyl group; and
R 2 is a hydrogen atom, and
R 3 is a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group; or
R 3 is a hydrogen atom, and R 2 is a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.
3. The method according to claim 1 , wherein
A represents a lower alkylene group;
R 1 represents an unsubstituted or substituted alkyl group;
R 2 represents an unsubstituted lower alkyl group or a lower alkyl group which is substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group; and
R 3 is a hydrogen atom.
4. The method according to claim 2 , wherein
A is a lower alkylene group;
R 1 is an unsubstituted or substituted lower alkyl group;
R 2 is a lower alkyl group substituted by a monocyclic cycloalkyl group or a polycyclic cycloalkyl group; and
R 3 is a hydrogen atom.
5. The method according to claim 4 , wherein A is a trimethylene group or a methyltrimethylene group; R 1 is a straight lower alkyl group which may have a substituent; R 2 is an adamantylethyl group or an adamantylpropyl group; and R 3 is a hydrogen atom.
6. The method according to claim 1 , wherein A is a lower alkylene group, R 1 is an unsubstituted alkyl group or a substituted alkyl group, R 2 is an unsubstituted lower alkyl group or a lower alkyl group substituted with a substituent selected from the group consisting of a monocyclic cycloalkyl group, a polycyclic cycloalkyl group and an aryl group.
7. The method according to claim 1 , wherein the compound is selected from the group consisting of:
1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea,
1-[2-(1-adamantyl)ethyl]-3-[3-(4-pyridyl)propyl]-1-(3,3,3-trifluoropropyl)urea,
1-[3-(1-adamantyl)propyl]-1-propyl-3-[3-(4-pyridyl)propyl]urea,
1-[2-(1-adamantyl)ethyl]-3-[1-methyl-3-(4-pyridyl)propyl]-1-pentylurea,
1-[2-(1-adamantyl)ethyl]-3-[2-methyl-3-(4-pyridyl)propyl]-1-pentylurea and
(+)-1-[2-(1-adamantyl)ethyl]-3-[2-methyl-3-(4-pyridyl)propyl]-1-pentylurea.
8. The method according to claim 1 , wherein the compound is 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea.
9. The method according to claim 1 , wherein the TRPV1-mediated disease is pain.
10. The method according to claim 1 , wherein the TRPV1-mediated disease is an overactive bladder.
11. The method according to claim 1 , wherein the TRPV1-mediated disease is a gastrointestinal dysfunction.